Detected ·
Slate Medicines
$245M—
Slate Medicines announced a definitive agreement to combine with Fulcrum Therapeutics in an all-stock transaction, alongside an oversubscribed $245M private financing led by Frazier Life Sciences. The combined company will focus on next-generation therapeutics for migraine and headache disorders, with lead program SLTE-1009 advancing through clinical stages.
- Website
- www.slatemedicines.com
- Amount
- $245 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-17 12:05:11 UTC
- Signal ID
- 27f007e8-eccf-46d8-b0b0-47da6c58a850
As the API returns it
{
"id": "27f007e8-eccf-46d8-b0b0-47da6c58a850",
"created_at": "2026-08-17T12:05:11.007451Z",
"company_name": "Slate Medicines",
"company_website_url": "www.slatemedicines.com",
"company_linkedin_url": "https://www.linkedin.com/company/slate-medicines",
"event_type": "funding",
"funding_amount": 245000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Slate Medicines announced a definitive agreement to combine with Fulcrum Therapeutics in an all-stock transaction, alongside an oversubscribed $245M private financing led by Frazier Life Sciences. The combined company will focus on next-generation therapeutics for migraine and headache disorders, with lead program SLTE-1009 advancing through clinical stages.*"
}